moexipril Side Effects
Also known as: Univasc
Analysis of 67 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
67
Death-Related
6
9.0% of reports
Hospitalizations
21
31.3% of reports
Top Indication
Hypertension
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 6 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 3 |
| DYSPNOEA | 2 |
| PNEUMONIA | 2 |
| ANHEDONIA | 1 |
| ANXIETY | 1 |
| ASTHENIA | 1 |
| CANDIDIASIS | 1 |
| CEREBROVASCULAR DISORDER | 1 |
| COUGH | 1 |
| DECREASED APPETITE | 1 |
| DISSEMINATED INTRAVASCULAR COAGULATION | 1 |
| DRUG INEFFECTIVE | 1 |
| DRUG TOXICITY | 1 |
| DYSPHAGIA | 1 |
| ECCHYMOSIS | 1 |
| ELECTROCARDIOGRAM QRS COMPLEX SHORTENED | 1 |
| EMOTIONAL DISTRESS | 1 |
| FATIGUE | 1 |
| FEAR | 1 |
| HEPATIC FAILURE | 1 |
Reactions in Hospitalization Reports
Top reactions in 21 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 5 |
| ASTHENIA | 4 |
| CEREBROVASCULAR ACCIDENT | 4 |
| DEHYDRATION | 4 |
| HEADACHE | 3 |
| HYPERTENSION | 3 |
| RENAL FAILURE ACUTE | 3 |
| ARTHROPATHY | 2 |
| BLOOD ALBUMIN DECREASED | 2 |
| BLOOD CREATINE PHOSPHOKINASE DECREASED | 2 |
| BLOOD CREATININE INCREASED | 2 |
| BLOOD PRESSURE DECREASED | 2 |
| BLOOD PRESSURE INCREASED | 2 |
| BLOOD UREA INCREASED | 2 |
| CHEST PAIN | 2 |
| CORONARY ARTERY DISEASE | 2 |
| CREATININE RENAL CLEARANCE DECREASED | 2 |
| DIALYSIS | 2 |
| DIZZINESS | 2 |
| HAEMOGLOBIN DECREASED | 2 |
Nearby — Related Medications
What the FAERS Data Reveals About moexipril Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 67 voluntary reports linked to moexipril and its brand equivalents (Univasc), spanning 2004 through 2025. Of those, 6 (9.0%) listed death as an outcome and 21 (31.3%) involved hospitalization. The most common indication reported alongside adverse events was Hypertension.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 68% were female and 32% male; age distribution skews toward 45-64, with 16 reports in that bracket. The single most reported reaction is asthenia with 8 submissions, followed by dyspnoea and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.